Lilly tests new drug LY3876602 in healthy people – no disease involved
NCT ID NCT06007638
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 39 times
Summary
This early-phase study tested the safety and tolerability of a new drug called LY3876602 in 74 healthy adults. Researchers gave single or multiple doses to see how the body processes the drug and how long it stays in the blood and spinal fluid. The goal was not to treat any disease, but to gather essential safety data for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON Early Phase Services, LLC
Groningen, 9728 NZ, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3876602
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.